期刊文献+

不同剂量瑞舒伐他汀对CHD并T2DM血脂、Hcy及血粘度的影响 被引量:2

Effects of different doses of rosuvastatin on blood lipids,Hcy and blood viscosity in CHD patients with T2DM
下载PDF
导出
摘要 目的 探讨不同剂量瑞舒伐他汀对冠心病(CHD)并2型糖尿病(T2DM)血脂、同型半胱氨酸(Hcy)及血粘度的影响。方法 回顾性选取2020年9月至2021年9月河北省第八人民医院收治的老年CHD合并T2DM患者162例,按照病历资料中治疗剂量的不同分为研究组(高剂量瑞舒伐他汀,n=81)和对照组(低剂量瑞舒伐他汀,n=81)。对比两组血脂、Hcy、血粘度、炎性因子、调节因子、血糖及不良反应。结果 治疗后各组HDL-C及Omentin-1水平上升、TC、TG、LDL-C、Hcy、血浆粘度、全血粘度、IL-6、TNF-α、hs-CRP水平、NF-κB水平水平皆降低,以研究组最明显,差异均有统计学意义(P<0.05)。治疗后,FPG、2h PG水平下降,差异有统计学意义(P<0.05);两组治疗前、治疗后FPG、2h PG水平比较差异无统计学意义(P>0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论 老年CHD合并T2DM患者采取高剂量瑞舒伐他汀降脂和抗炎效果更强,能更有效改善患者血脂、Hcy、血粘度、NF-κB、Omentin-1及血糖水平,减轻炎性反应,且安全性尚可。 Objective To explore the effect of different doses of rosuvastatin on blood lipid,homocysteine(Hcy)and blood viscosity in patients with coronary heart disease(CHD)and type 2 diabetes mellitus(T2DM). Methods 162 elderly patients with CHD complicated with T2DM who were admitted to the Eighth People ’ s Hospital of Hebei Province from September 2020 to September 2021 were retrospectively selected,and according to the the medical records of different doses of treatment,they were divided into the study group(high-dose rosuvastatin,n=81)and the control group(low-dose rosuvastatin,n=81). Blood lipids,Hcy,blood viscosity,inflammatory factors,regulatory factors and adverse reactions were compared between the two groups. Results After treatment,the levels of HDL-C and Omentin-1 increased,TC,TG,LDL-C,Hcy,plasma viscosity,whole blood viscosity,IL-6,TNF-α,Hs-CRP and NF-κB levels decreased in tow groups. The decrease was the most obvious in the study group,and the difference was statistically significant(P<0.05). After treatment,the levels of FPG and 2h PG decreased,and the differences were statistically significant(P<0.05).There was no significant difference in the FPG and 2h PG levels between the two groups before and after treatment(P>0.05). There was no difference in adverse reactions between the two groups(P>0.05).Conclusion High-dose rosuvastatin has better lipid-lowering and anti-inflammatory effects in elderly patients with CHD complicated with T2DM,and can more effectively improve the levels of blood lipid,Hcy,blood viscosity,NF-κB,omentin-1 and blood glucose,reduce the inflammatory response,and the safety is acceptable.
作者 李秀丽 赵芳 石美丽 于姗 张丽敏 路康 刘玮琳 LI Xiuli;ZHAO Fang;SHI Meili;YU Shan;ZHANG Limin;LU Kang;LIU Weilin(the Second Department of Cardiology,the Eighth People's Hospital of Hebei Province,Shijiazhuang,Hebei,China,050011;Department of Respiratory and Nephrology,the Eighth People's Hospital of Hebei Province,Shijiazhuang,Hebei,China,050011;Department of Endoscopy Room,the Eighth People's Hospital of Hebei Province,Shijiazhuang,Hebei,China,050011;Department of Laboratory Medicine,the Eighth People's Hospital of Hebei Province,Shijiazhuang,Hebei,China,050011)
出处 《分子诊断与治疗杂志》 2022年第11期1862-1866,共5页 Journal of Molecular Diagnostics and Therapy
基金 河北省医学科学研究课题计划(20220797)。
关键词 瑞舒伐他汀 OMENTIN-1 HCY 冠心病 NF-κB 2型糖尿病 Rosuvastatin Omentin-1 Hcy Coronary heart disease NF-κB Type 2 diabetes
  • 相关文献

参考文献8

二级参考文献64

共引文献144

同被引文献25

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部